Custom Approach to Enhance Clinical Data Mining
News Oct 01, 2014
LabConnect’s BioVisualization is a proprietary and customizable software platform that queries clinical sample database(s) in real time to analyze and provide visual interpretations of a project’s data. This unique platform is designed to quickly generate customizable figures, which can be downloaded and shared among colleagues and incorporated into reporting documents.
“Large, complex datasets generated throughout the course of a clinical trial make finding underlying trends challenging,” said Eric Hayashi, president and CEO. “LabConnect’s BioVisualization tool makes it possible to visualize this data and find greater meaning using fewer resources. This inventive platform creates an opportunity to make critical decisions a lot sooner.”
LabConnect’s white paper, “BioVisualization: Custom Approaches to Enhance Clinical Data Mining,” provides an overview of visual data analysis tools, their benefits and how this technology is being implemented by pharmaceutical companies of all sizes to make critical decisions faster and with lower costs. This informative white paper is now available for download.
“The scale of datasets has become overwhelming, making analysis of this information tedious and resource-draining,” said Hermioni Zouridis, senior scientist of scientific operations at LabConnect. “Unlike pre-programmed platforms, versatile visual data analytics tools enable researchers to generate customizable figures, helping identify trends in study results faster and ultimately making it possible to bring drugs to market sooner.”
HIV-1 replicates in ninja-like ways. The virus slips through the membrane of vital white blood cells. Inside, HIV-1 copies its genes and scavenges parts to build a protective bubble for its copies. Now, supercomputers have helped model a key building block in the HIV-1 protective capsid, which could lead to strategies for potential therapeutic intervention in HIV-1 replication.READ MORE
Mood disorders like major depressive disorder (MDD) and bipolar disorder are often complex and hard to diagnose, especially among youth when the illness is just evolving. This can make decisions about medication difficult. In a collaborative study by Lawson Health Research Institute, The Mind Research Network and Brainnetome Center, researchers have developed an artificial intelligence (AI) algorithm that analyzes brain scans to better classify illness in patients with a complex mood disorder and help predict their response to medication.